Turbine, a leading developer of cell simulations with AI, today announced a research collaboration with MSD (the tradename of ...

Recent developments in antiretroviral therapy (ART) include longer-acting therapies that don't require a daily oral pill and ...

The neuroendocrine prostate cancer treatment space will experience significant changes during the forecast period of 2025–2034, owing to the launch o ...

A mum who enrolled in a college course after her son’s type 1 diabetes diagnosis is now building a successful career in science after 20 years ...

The dollar (.DXY) is on course for its best week of the year, as unfolding U.S. trade deals are succeeding in raising tariffs ...

Employees of the technology transfer centre ANAXAM and researchers from the Paul Scherrer Institute PSI used the unique ...

Employees of the technology transfer centre ANAXAM and researchers from the Paul Scherrer Institute PSI used the unique ...

Media Release The pivotal TACTI-004 Phase III trial in first line non-small cell lung cancer (1L NSCLC) continues to build ...

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ('Immutep” or 'the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an upcoming poster presentation for ...

Adrenocortical Carcinoma Market Forecast upto 2034—Insights into Emerging Therapies and Market Trends | DelveInsight The adrenocortical carcinoma market in the 7MM is anticipated to boost during the ...

Media Release The pivotal TACTI-004 Phase III trial in first line non-small cell lung cancer (1L NSCLC) continues to build momentum and is recruiting patients at a growing number of activated clinical ...